Avidity Biosciences reports wider-than-expected Q3 net loss

Reuters

Nov 11, 2025

<a href="https://laohu8.com/S/RNA">Avidity Biosciences</a> reports wider-than-expected Q3 net loss

Overview

Avidity reports Q3 net loss, missing analyst expectations
Strong cash position of $1.9 bln to fund operations to mid-2028

Outlook

Avidity plans BLA submission for del-zota in 2026
Merger with Novartis expected to close in H1 2026
54-week topline data for del-desiran expected in H2 2026

Result Drivers

R&D EXPENSES - Increased R&D expenses due to advancement of clinical programs and higher personnel costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$12.48 mln
Q3 Net Income	Miss	-$174.44 mln	-$149.39 mln (11 Analysts)
Q3 Basic EPS		-$1.27
Q3 Operating Expenses		$201.28 mln
Q3 Operating Income		-$188.81 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Avidity Biosciences Inc is $72.00, about 3% above its November 7 closing price of $69.84

Press Release: ID:nPn8f472wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582889953"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582889953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582889953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582889953","market":"fut","top_or_hot":-1,"title":"Avidity Biosciences reports wider-than-expected Q3 net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> reports wider-than-expected Q3 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>Avidity reports Q3 net loss, missing analyst expectations</p></li><li><p>Strong cash position of $1.9 bln to fund operations to mid-2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Avidity plans BLA submission for del-zota in 2026</p></li><li><p>Merger with Novartis expected to close in H1 2026</p></li><li><p>54-week topline data for del-desiran expected in H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses due to advancement of clinical programs and higher personnel costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$12.48 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$174.44 mln</p></td><td><p>-$149.39 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$1.27</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$201.28 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$188.81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Avidity Biosciences Inc is $72.00, about 3% above its November 7 closing price of $69.84</p></li></ul><p>Press Release: <span>ID:nPn8f472wa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences reports wider-than-expected Q3 net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences reports wider-than-expected Q3 net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> reports wider-than-expected Q3 net loss</title></head><body><p><span>Overview</span></p><ul><li><p>Avidity reports Q3 net loss, missing analyst expectations</p></li><li><p>Strong cash position of $1.9 bln to fund operations to mid-2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Avidity plans BLA submission for del-zota in 2026</p></li><li><p>Merger with Novartis expected to close in H1 2026</p></li><li><p>54-week topline data for del-desiran expected in H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses due to advancement of clinical programs and higher personnel costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$12.48 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$174.44 mln</p></td><td><p>-$149.39 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$1.27</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$201.28 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$188.81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Avidity Biosciences Inc is $72.00, about 3% above its November 7 closing price of $69.84</p></li></ul><p>Press Release: <span>ID:nPn8f472wa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM11Z:1","article_id":"2582889953","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582889953","pubTimestamp":1762809650,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avidity Biosciences reports wider-than-expected Q3 net lossOverviewAvidity reports Q3 net loss, missing analyst expectationsStrong cash position of $1.9 bln to fund operations to mid-2028OutlookAvidit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","RNA":"Atrium Therapeutics"},"translate_title":"Avidity Biosciences报告第三季度净亏损超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"Avidity Biosciences reports wider-than-expected Q3 net lossOverviewAvidity reports Q3 net loss, missing analyst expectationsStrong cash position of $1.9 bln to fund operations to mid-2028OutlookAvidity plans BLA submission for del-zota in 2026Merger with Novartis expected to close in H1 202654-week topline data for del-desiran expected in H2 2026Result DriversR&D EXPENSES - Increased R&D expenses due to advancement of clinical programs and higher personnel costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$12.48 mlnQ3 Net IncomeMiss-$174.44 mln-$149.39 mln (11 Analysts)Q3 Basic EPS-$1.27Q3 Operating Expenses$201.28 mlnQ3 Operating Income-$188.81 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 10 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Avidity Biosciences Inc is $72.00, about 3% above its November 7 closing price of $69.84Press Release: ID:nPn8f472waFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}